DS
ACAD icon

DRW Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

DRW Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Buy
17,111
+8,118
+90% +$179K 0.01% 468
2026
Q1 		$200K Buy
+8,993
New +$215K ﹤0.01% 1119
2025
Q3 		– Sell
-10,047
Closed -$222K – 1255
2025
Q2 		$222K Buy
+10,047
New +$187K 0.01% 907

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DRW Securities's ACAD Position: Q2 2026 in Review

DRW Securities increased its Acadia Pharmaceuticals (ACAD) stake by 90% in Q2 2026, buying an estimated $179K and bringing the position to 17,111 shares worth $433K. The position accounts for 0.01% of the portfolio, ranked #468.

DRW Securities first reported a position in ACAD in Q2 2025 and has held it in 3 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • DRW Securities held 17,111 shares of Acadia Pharmaceuticals worth $433K as of Q2 2026.
  • DRW Securities bought 8,118 Acadia Pharmaceuticals shares in Q2 2026, an estimated $179K.
  • Acadia Pharmaceuticals made up 0.01% of DRW Securities's portfolio in Q2 2026, its #468 holding.
  • DRW Securities first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.